LncRNA UCA1 promotes SOX12 expression in breast cancer by regulating m6A modification of miR-375 by METTL14 through DNA methylation

• Published in: Cancer gene therapy Vol. 29; no. 7; pp. 1043 - 1055
• Main Authors: Zhao, Chengpeng, Ling, Xiaoling, Xia, Yunxia, Yan, Bingxue, Guan, Quanlin
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.07.2022; Nature Publishing Group
• Subjects: 13/109; 13/51; 692/699/67; 692/699/67/1347; Apoptosis; Bioinformatics; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cell proliferation; Cholecystokinin; DNA methylation; DNA methyltransferase; Flow cytometry; Gene Expression; Gene Therapy; Morbidity; N6-methyladenosine; Non-coding RNA; Risk factors; Tumors; Xenografts
• DOI: 10.1038/s41417-021-00390-w
• ISSN: 0929-1903; 1476-5500

Breast cancer, a multifactorial disease, represents one of the leading causes of cancer-related morbidity and mortality in women. This study set out to elucidate the underlying mechanism by which lncRNA UCA1 affects the m 6 A modification of miR-375 by mediating the DNA methylation of METTL14 and then altering SOX12 expression in breast cancer. First, the expression patterns of lncRNA UCA1, miR-375, and apoptosis-related factors were quantitated by means of RT-qPCR and western blot analysis. In addition, the proliferation, invasion, and apoptosis of cells were detected using CCK-8, Transwell, and flow cytometry, respectively. RIP was performed to further uncover the interaction of lncRNA UCA1 and DNA methyltransferases, and MSP was employed for METTL14 promoter region methylation. The DNA methyltransferase enrichment in the METTL14 promoter region was measured by ChIP. The targeting relationship between miR-375 and SOX12 was confirmed by bioinformatics analysis and dual-luciferase report assay. Lastly, the aforementioned mechanism was also verified using tumor xenograft in vivo. It was found the elevated lncRNA UCA1 expression levels serve as a risk factor of poor prognosis in breast cancer. Meanwhile, silencing lncRNA UCA1 could inhibit the proliferation and invasion, but promote apoptosis of breast cancer cells by reducing the DNA methylation of METTL14 and augmenting its expression. Furthermore, METTL14 was observed to mediate the low miR-375 expression through m 6 A modification, leading to increased SOX12 expression levels in breast cancer. Altogether, findings obtained in our study indicated that silencing lncRNA UCA1 curbed the progression of breast cancer through the METTL14-miR-375- SOX12 axis.